PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PROCEPT BioRobotics Corp achieves record revenue growth, eyes market expansion

PROCEPT BioRobotics Corp demonstrated strong financial growth in Q4 2022, with revenue surging by 135% year-over-year, setting the stage for continued expansion and market success.
While facing challenges such as high operating expenses and margin pressures, the company remains focused on innovation, market diversification, and operational improvements to drive future profitability.
With a clear strategy to enhance sales efforts, expand market reach, and invest in R&D, PROCEPT BioRobotics Corp is well-positioned to capitalize on growth opportunities and solidify its presence in the medical technology sector.
Overall, the company's performance highlights a balance between revenue growth initiatives, cost management strategies, and a commitment to delivering high-quality healthcare solutions, signaling a positive outlook for future success.

PROCEPT BioRobotics Corp reports strong Q1 growth and eyes global expansion

PROCEPT BioRobotics Corp delivered strong Q1 results with robust revenue growth and margin expectations, despite profitability challenges.
The company's focus on long-term growth, pricing discipline, and market opportunities position it well for future success and becoming a standard of care for BPH.
While facing challenges like operating expenses and sales performance, PROCEPT BioRobotics remains optimistic about international expansion and market potential.
With a solid financial foundation, high surgeon retention rates, and exciting growth prospects in new markets, the company is poised for continued success.

PROCEPT BioRobotics Corp achieves record revenue and strategic partnerships

PROCEPT BioRobotics delivered a standout performance in Q2 2023, marked by record revenue, strong U.S. system sales, and international growth, supported by strategic partnerships and positive payer coverage updates.
While facing challenges from dilutive effects of new system placements and market evaluation complexities, the company's focus on innovation, financial strength, and growth opportunities position them well for future success.
By capitalizing on the momentum in system sales, expanding market reach, and leveraging the trend towards innovative treatments, PROCEPT BioRobotics is poised for continued growth and market leadership in the healthcare sector.

PROCEPT BioRobotics reports record Q3 revenue and eyes international expansion

PROCEPT BioRobotics delivered a strong quarter marked by revenue growth, improved gross margin, and strategic equity financing, positioning the company for future success.
While facing challenges in profitability and international sales, the company's focus on cost control, expansion, and innovative therapies presents avenues for growth and market leadership.
Overall, PRCT's performance reflects resilience and strategic foresight, supported by a confident management team and a clear vision for sustained growth and profitability.

PROCEPT BioRobotics Corp reports robust revenue growth and strategic focus

PROCEPT BioRobotics Corp delivered strong revenue growth in Q4 2023 and provided optimistic guidance for 2024, focusing on gross margin expansion and disciplined expense management.
The company's strategic strengths lie in innovation, customer base expansion, and patient awareness initiatives, while challenges include managing operating expenses and market dynamics.
Opportunities for PROCEPT include leveraging R&D investments, patient education, and market presentations to capture a larger share of the BPH patient population and drive utilization growth.
Overall, PROCEPT's performance highlights its commitment to long-term value creation, market stability, and strategic growth initiatives in the medical robotics sector.

PROCEPT BioRobotics Corp reports strong revenue growth and strategic advancements

PROCEPT BioRobotics Corp delivered strong revenue growth in Q1 2024, driven by robust U.S. sales and improved gross margins. The company's strategic focus on profitability, customer relationships, and product safety positions it well for future success.
While facing challenges with net losses and high operating expenses, PROCEPT BioRobotics Corp has opportunities to drive growth through ASC procedures, international expansion, and clinical trials. Leveraging strategic partnerships and market-leading products will be key to overcoming challenges and seizing opportunities.
Overall, PROCEPT BioRobotics Corp's Q1 performance reflects a mix of strengths, challenges, and opportunities. By navigating financial hurdles, capitalizing on market trends, and maintaining a customer-centric approach, the company can drive sustainable growth and enhance its competitive position.

PROCEPT BioRobotics reports strong revenue growth but faces profitability challenges

PROCEPT BioRobotics delivered robust revenue growth and margin expansion in Q2 2024, driven by strong U.S. sales and operational efficiency. However, escalating operating expenses led to a net loss and negative adjusted EBITDA.
The company's strategic focus on leveraging fixed costs and sustaining revenue growth presents opportunities for long-term profitability and market expansion. Balancing cost control with revenue generation will be crucial for future success.
Despite challenges in achieving profitability, PROCEPT BioRobotics remains confident in its ability to drive margin expansion through increased revenues and operational efficiencies, positioning itself for sustained growth and financial improvement.

PROCEPT BioRobotics excels in Q3 with revenue surge and innovation

PROCEPT BioRobotics delivered strong revenue growth, margin improvement, and operational progress in Q3 2024, underpinned by market acceptance and innovation.
While facing challenges in managing expenses and achieving profitability, the company's solid financial position and growth outlook offer opportunities for future success.
By focusing on cost optimization, product differentiation, and strategic investments, PROCEPT can navigate challenges and leverage opportunities to drive sustained growth and value creation.
Overall, PROCEPT's performance reflects resilience and potential for continued expansion in the robotic medical systems market, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates.

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaway - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics Third Quarter 2024 Earnings Conference Call. At this time all participants' are in a listen-only mode.

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Procept Biorobotics shares surged Monday after the robotic surgery player beat September-quarter expectations and hiked its outlook.

Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024.

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

PROCEPT BioRobotics (PRCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -15.71% in 4 Weeks, Here's Why PROCEPT BioRobotics (PRCT) Looks Ripe for a Turnaround

PROCEPT BioRobotics (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.

PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

The FDA's approval of Procept's Hrydos system is a meaningful catalyst to the investment debate. Investors have added ~$5/share in market value since the announcement. PRCT's Q2 '24 numbers were equally as strong and exhibited an extensive runway of growth ahead in my view.

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.

PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Dynatrace Inc

Zebra Technologies

While the global industrial automation market is poised for a CAGR of 8.3% between 2024 and 2031, according to SkyQuest, it bears winnowing out the particulars of the market, including identifying robotics stocks to sell. With signals pointing to global economic slowdown and the reduction in capital expenditures, robotics investments may also suffer.

3 Robotics Stocks to Sell in August Before They Crash & Burn

Surgical robotics company PROCEPT BioRobotics Co. NASDAQ: PRCT developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia (BPH) among aging men. The company went public during the special purpose acquisition company (SPAC) mania in 2021.

Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive VP, Chief Commercial Officer Kevin Waters - Executive VP, Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Richard Newitter - Truist Brandon Vasquez - William Blair Joshua Jennings - TD Cowen Dino Weinstock - Wells Fargo Ryan Zimmerman - BTIG Operator Good afternoon and welcome to PROCEPT BioRobotics Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

PROCEPT BioRobotics Corporation (PRCT) Q2 2024 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.56 per share a year ago.

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024.

News for PROCEPT BioRobotics Corp Stock (PRCT)